Why Ozempic Costs So Much: The Patent Story Every Patient Should Know
Ozempic costs €300+ per month in some countries and €14 in others. Here's the patent economics behind the price — and why 2026 is changing everything.
In Rotterdam, a monthly supply of Ozempic costs about €320. In Toronto, about CAD $350. In São Paulo, about R$963. In Mumbai, Ozempic costs around ₹10,000, but a genuine generic alternative costs ₹1,290 — roughly €14.
Same molecule. Same effect. A 20× price difference. That's not a mistake. That's how drug patents work, and understanding the story is the single most useful thing you can do before you spend a euro, a rupee, or a real on a GLP-1 weight management programme.
The basic math of drug development
Developing a new medication is expensive. Nobody sensible disputes this. For a blockbuster like semaglutide, Novo Nordisk spent an estimated USD $2–3 billion on research, clinical trials, regulatory submissions, and the manufacturing build-out before the drug earned back a single dollar. They studied it in diabetes for years before the weight-loss indication emerged. They ran cardiovascular outcomes trials that followed patients for years. They won approval in every major regulated market. That costs money.
To give drug companies a reason to make that investment, every country signed international agreements that grant a patent on new medicines — typically 20 years from the date the original patent was filed, though effective protection is usually shorter because clinical trials eat into the term.
During the patent period, the company that invented the drug is the only one legally allowed to make and sell it in countries where the patent is active. They can charge whatever price the market will bear. For semaglutide, Novo Nordisk chose to charge a premium because demand was massive and competition was zero.
What that premium actually looks like
As of early 2026, before generics arrived in most markets, the list prices for branded semaglutide products looked roughly like this:
| Country | Product | Monthly cost | ~USD |
|---|---|---|---|
| Netherlands | Ozempic 0.5 mg | €220–320 | $245–360 |
| Netherlands | Wegovy | €220–369 | $245–410 |
| United Kingdom | Wegovy | £150–250 | $190–315 |
| Canada | Ozempic | CAD $250–400 | $185–300 |
| Brazil | Ozempic 0.5 mg | R$963 | $195 |
| India | Ozempic | ₹8,800–11,175 | $105–135 |
| India | Wegovy | ₹16,400 | $197 |
| United States | Wegovy | $1,000+ (list) | $1,000+ |
A few things jump out of this table:
Why the patent expires — and what that means
A patent isn't permanent. Semaglutide's original patent was filed in the mid-2000s. Twenty years later, in 2026, the protection begins to expire — but not everywhere at the same time.
2026 — the year the semaglutide generic wave begins
The earliest patent expiries are happening right now:
The next wave is later:
What's happening in the first-wave countries is that licensed generic manufacturers — Sandoz and Apotex in Canada; Natco, Sun Pharma, Dr Reddy's, Zydus, Alkem, Glenmark, Cipla, Lupin and others in India — have been preparing to launch the moment the patent drops. And they have launched. In India specifically, there were generic products on pharmacy shelves within 48 hours of the patent expiry date.
What happens to the price when generics arrive
History tells a consistent story: when a blockbuster drug goes off-patent and multiple generic manufacturers launch at once, prices typically drop by 70–90% within the first six months. This has happened with statins (atorvastatin, Lipitor), with proton-pump inhibitors, with many oncology drugs, and most recently with several biologic medicines.
Semaglutide is following the same pattern, but faster, because the demand is enormous and multiple manufacturers were ready to launch simultaneously. In India, within three weeks of patent expiry, the cheapest authorised generic was selling at ₹1,290 per month — a 90% reduction from the branded price of ₹11,000–16,000.
This isn't a sale. It isn't a promotion. It isn't going to go back up once the "launch offer" ends. It is simply what semaglutide costs to manufacture, package, ship, and sell, with a reasonable generic-manufacturer margin on top. The branded price was the patent premium. The generic price is the actual cost.
The uncomfortable question for patients in "late" markets
If you live in India, Canada, or Brazil, the generic wave is either already here or very close. If you live in the United States, the UK, the Netherlands, or most of the European Union, you are still paying the patent premium — and you will continue to pay it until your country's patent clock runs out.
This creates an uncomfortable reality: the same medication that costs €14 per month in Mumbai costs €220+ per month in Amsterdam, and will continue to cost €220+ in Amsterdam until approximately 2031. That is not a market inefficiency. That is patent protection working exactly as it was designed to work — funding pharmaceutical innovation by granting a time-limited monopoly.
Whether that's fair is a separate question, and it's one that healthcare systems, insurance companies, and patients all over the world are grappling with right now.
Where Magistra fits in
We built Magistra because we believe the 2026 generic wave is the most important pricing event in weight management medicine of the decade, and patients should be able to benefit from it wherever they live, not wherever the nearest authorised generic has been shipped.
Our model is simple: we source authentic, regulator-approved generic semaglutide directly from the manufacturers who are licensed to produce it, and we deliver it through local licensed doctors and pharmacies to patients in the countries where it is legally available. We don't compound. We don't make our own. We don't work with grey-market suppliers. The medication you get is the same medication you would get if you walked into a pharmacy in the country where it was manufactured — except we handle the prescription, the consultation, the cold chain, and the ongoing care.
In the countries where the patent is still active (most of the EU, US, UK), we're building, waiting, and watching the clock. When the patent drops, we'll be ready.
What you should do right now
If you're considering a GLP-1 weight management programme:
This article is educational and not a substitute for medical advice. Semaglutide is a prescription medication and should only be used under the supervision of a licensed healthcare provider. Prices quoted are approximate and change frequently — always verify with a local pharmacy before relying on a specific number.
Related reading:
Want to be notified when Magistra launches in your country? Join the waitlist.
Klaar om te beginnen?
Vul een korte vragenlijst in en ontdek of een gepersonaliseerd programma bij je past.
Begin Nu